New Cancer Drug Shrinks Tumors in 62% of Lung Patients

Patients with advanced pancreatic and lung cancers just got a promising new reason for hope.

Biotech company Erasca announced Monday that its experimental pill, ERAS-0015, shrank tumors in 40% of advanced pancreatic cancer patients and an impressive 62% of patients with advanced non-small cell lung cancer. The results came from clinical trials conducted across the United States and China, exceeding the company's own expectations.

The drug works by targeting RAS, a protein that fuels cancer growth in many hard-to-treat tumors. For decades, scientists struggled to develop medications that could effectively block RAS, but recent breakthroughs have finally cracked the code.

"I'm excited about both datasets, but I think lung is more definitive at this point," said Erasca CEO Jonathan Lim. He noted that while the lung cancer data looks strongest so far, the pancreatic cancer results remain "very, very promising" as more information comes in.

Pancreatic cancer remains one of the deadliest cancer diagnoses, with most patients surviving less than a year after diagnosis. Non-small cell lung cancer, while more treatable than in the past, still claims over 120,000 American lives annually. Any therapy that can shrink tumors in these aggressive cancers represents a significant step forward.

The drug's performance appears competitive with similar treatments already showing success. Erasca compared their results favorably to daraxonrasib, another RAS-targeting drug from Revolution Medicines that recently doubled overall survival in advanced pancreatic cancer patients.

The Ripple Effect

The success of ERAS-0015 adds to a growing wave of RAS-targeting therapies transforming cancer treatment. After decades of dead ends, multiple companies now have promising drugs in development, creating healthy competition that could speed up access for patients. When one breakthrough succeeds, it validates the science and encourages more investment in similar approaches.

This rising tide of RAS inhibitors means oncologists may soon have multiple options to choose from when treating their toughest cases. Different drugs work better for different patients, so having a toolkit rather than a single option could help doctors personalize treatment more effectively.

The preliminary data still needs confirmation through larger, longer studies before the FDA can approve ERAS-0015 for widespread use. But for patients and families facing these devastating diagnoses, watching multiple companies race toward better treatments offers something precious: genuine reasons for optimism.

Thousands of patients enrolled in clinical trials are already benefiting from these next-generation cancer fighters.